The ALS Association Accelerates Search for Lou Gehrig's Disease Genes
Unprecedented Research Effort Mirrors The ALS Association's
Aggressive Search for a Cure
CALABASAS HILLS, Calif., July 16 /PRNewswire/ -- The ALS Association (ALSA), the only national not-for-profit organization dedicated solely to the fight against amyotrophic lateral sclerosis (ALS), today announced it has launched a major research project that would significantly reduce the time taken to identify the genes that cause ALS, more commonly referred to as Lou Gehrig's disease. ALS is a fatal disease that attacks the motor neurons in the brain and spinal cord and has no known cure. The $1.5 million project is a collaboration among world-renown geneticists and scientists. This study represents the largest research grant ever given by The ALS Association for a single project and is among the largest ever in Lou Gehrig's disease research. "The discovery of more genes that link to ALS is crucial for our understanding of disease mechanisms and may provide new targets for therapy," said Lucie Bruijn, Ph.D., science director and vice president, The ALS Association. By accelerating the process of discovering genes linked to Lou Gehrig's disease, researchers hope to provide an important new roadmap for scientists to use to speed the discovery of new therapies and cures for ALS and other diseases. About the Research Project Human geneticists and scientists will apply technology used in the Human Genome Project to find new genes and mutations linked to familial (passed within families) ALS. The research project is to be executed in three phases. The first phase involves development of BAC (bacterial artificial chromosome) libraries from familial ALS patients to enable the sequencing of large regions of the chromosome linked to familial ALS. Sequencing of the BAC libraries will form the second phase of the project. As many sequence variations may be present both in normal and disease populations, sequence changes (mutations) unique to the patient population must be identified -- this represents the third phase of the project. "This international collaboration to identify new genes linked to familial ALS is among the most exciting and potentially informative projects we have initiated," said Dr. Tom Maniatis, professor of molecular and cellular biology, Harvard University and head of The ALS Association's Cure ALS Advisory Committee. "We are very fortunate to have the outstanding human geneticists who have identified new ALS loci (regions), working closely with scientists who played central roles in sequencing the human genome. If successful, this effort will not only identify ALS genes associated with currently identified familial loci, but will advance the technology required to identify additional ALS genes in the future." The discovery of the Cu/Zn superoxide dismutase 1 (SOD1) gene on chromosome 21 linked to 20 percent of familial ALS, almost a decade ago and more than a century after ALS was first identified, was a significant milestone in ALS research. The results from this new study are expected to advance the overall understanding of Lou Gehrig's disease. It will enable the development of animal models scientists can use to test a variety of disease hypotheses and therapies and even find a cure for this disease. "There is no doubt that discovery of new causes of familial ALS will illuminate our understanding of non-familial (sporadic) ALS. It is even possible the new insights will be relevant to other brain degeneration diseases," said Dr. Robert Brown of the Massachusetts General Hospital. Sporadic ALS accounts for 90 percent of all ALS cases. "Using the same technology as that used in the Human Genome Project enables us to more systematically and rapidly sequence through large regions of the genome to identify genes linked to disease. It's more efficient and cost effective," says Dr. Eric Lander, director of the Whitehead Institute Center for Genome Research, who will spearhead this effort. "Also, using genomic DNA from ALS patients is the most direct and reliable way to identify ALS-linked genes." A distinctive characteristic of the project is the collaboration it has fostered among some of the finest minds in the field of human genetics. Scientists participating in this effort include Dr. Robert Brown of Massachusetts General Hospital; Dr. Guy Rouleau of Montreal General Hospital; Dr. Jackie de Belleroche of Imperial College, Charring Cross Hospital, London, England; and Dr. Teepu Siddique of Northwestern University. In addition, Dr. Pieter J. de Jong, Children's Hospital Oakland Research Institute, will generate BAC libraries from cell lines prepared by GMP Companies, Inc. Dr. Eric Lander of the Whitehead Institute Center for Genome Research, will direct the sequencing phase of the project. About ALS Research The ALS Association is the largest private source of funding for ALS-specific scientific research in the world. This gene identification project will broaden The ALS Association's already diverse research portfolio. The ALS Association continues to aggressively seek new and under-researched areas, knowing fully the risks involved, but at the same time realizing the importance of such an approach in order to find effective therapies and, eventually, a cure for this dreaded disease. The ALS Association has initiated a number of promising new directions in ALS research, ranging from stem-cell research, to the development of new animal models for ALS, to the establishment of cell-based assays and screening for potential drugs to treat ALS. About ALS Amyotrophic lateral sclerosis (ALS), more commonly referred to as Lou Gehrig's disease, is a fatal, neurodegenerative disease that attacks nerve cells and pathways in the brain and spinal cord. When these cells die, the ability of the brain to start and control all voluntary muscle control and movement dies with them. Patients in the later stages of the disease are totally paralyzed, yet in most cases, their minds remain sharp and alert. About The ALS Association The ALS Association is the only national not-for-profit voluntary health organization dedicated solely to the fight against ALS through research, patient support, advocacy, and public awareness. The Association and its widespread network of volunteer-led Chapters and support groups, along with its certified ALS clinics, wage battle against the disease. For more information about ALS and The ALS Association, visit www.alsa.org . MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X02745885
SOURCE The ALS Association
More by this Source
New ALS Gene Strengthens Focus on RNA Processing
Mar 31, 2014, 11:05 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.